ARTICLE | Clinical News
NeoPharm to continue brain cancer trial
June 28, 2005 1:04 AM UTC
NEOL said a DMC recommended continuation of the Phase III PRECISE trial of cintredekin besudotox (IL13-PE38QQR) in patients with glioblastoma multiforme. The trial has enrolled 200 patients. The first...